Novo Nordisk A/S (NONOF) Stock

About Novo Nordisk A/S

Novo Nordisk A/S operates as a prominent global pharmaceutical firm, dedicated to the discovery, development, production, and distribution of a wide array of medicinal products. Its extensive operations are primarily structured into two distinct divisions: Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment offers comprehensive solutions, encompassing various insulin preparations, GLP-1 receptor agonists along with their delivery systems, oral antidiabetic medications, treatments for weight management, and therapies addressing other chronic health conditions. Meanwhile, the Biopharmaceuticals division is focused on specialized treatments for hemophilia, growth hormone disorders, and hormone replacement therapy. The company actively engages in strategic collaborations, notably including an agreement with Gilead Sciences, Inc. Furthermore, Novo Nordisk A/S is engaged in a research partnership with Lumen Bioscience, Inc., aiming to explore innovative methods for administering oral biologics for the management of cardiometabolic diseases. Established in 1923, the company's main corporate offices are located in Bagsvaerd, Denmark.

Novo Nordisk A/S is headquartered in DK.

Novo Nordisk A/S (NONOF) stock trades at $47.27 with a market capitalization of $209.91B. The stock is valued at a price-to-earnings (P/E) ratio of 11.68, price-to-book of 6.13, price-to-sales of 4.13. Over the past 52 weeks the stock has ranged between $34.00 and $64.75, and currently trades 27.0% below its 52-week high. It pays a dividend yielding 5.16%.

On profitability, Novo Nordisk A/S generates a return on equity (ROE) of 59.09% — well above the market average, a sign of a high-quality business, return on capital employed of 39.93%, an operating margin of 43.13%, a net profit margin of 35.35%.

In its most recent fiscal year, Novo Nordisk A/S reported annual revenue of $308.4B, net profit of $102.2B, revenue has compounded at 19.4% a year over the last five years, profit at 19.4% a year.

The balance sheet shows a debt-to-equity ratio of 0.63, a current ratio of 0.87, total assets of $541.7B, $26.4B in cash and equivalents.

NONOF has an average daily trading volume of 16,782 shares, a beta of 0.35 (less volatile than the overall market).

Official website: www.novonordisk.com